Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4551293 | 0.76 | ALDH1A1 (0.60) | LMNAGAAPYCR1AOC3ALDH1A1 | |
| SCHEMBL5542194 | 0.74 | KCNA5 (0.50) | LMNAPYCR1ALDH1A1KCNA5KMT2A | |
| SCHEMBL12128225 | 0.72 | L3MBTL1 (0.56) | TAAR1KDM4EAOC3KCNH2L3MBTL1 | |
| SCHEMBL12128173 | 0.72 | L3MBTL1 (0.56) | TAAR1KDM4EAOC3KCNH2L3MBTL1 | |
| SCHEMBL654154 | 0.72 | TAAR1 (0.56) | TAAR1KDM4ELMNAALDH1A1KCNH2 | |
| SCHEMBL7326431 | 0.72 | ALDH1A1 (0.50) | TAAR1AOC3ALDH1A1KMT2AMEN1 | |
| SCHEMBL16226366 | 0.71 | KCNH2 (0.55) | KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30274293 | 0.71 | L3MBTL1 (0.50) | TAAR1KDM4ELMNAGAAAOC3 | |
| SCHEMBL4550659 | 0.70 | ALDH1A1 (0.52) | KDM4ELMNAGAAPYCR1AOC3 | |
| SCHEMBL21153738 | 0.69 | GAA (0.53) | TAAR1KDM4ELMNAGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | ACELOT,INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | ACELOT, INC. | 2020-07-16 | — | — | US | disclosed |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | ACELOT, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | ACELOT, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | APP, PSEN2, PSEN1 | TAAR1 2452/4885KDM4E 4863/4885LMNA 635/4885 |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | APP, PSEN2, PSEN1 | TAAR1 1901/4885KDM4E 4816/4885LMNA 571/4885 |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | APP, PSEN2, PSEN1 | TAAR1 2452/4885KDM4E 4863/4885LMNA 635/4885 |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | HTT, TARDBP, SNCA | TAAR1 1767/4885KDM4E 4369/4885LMNA 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.